Mira ChaurushiyaPartner at 5AM Ventures
Mira Chaurushiya, Ph.D. is a Partner at 5AM Ventures and joined the firm in 2015. Dr. Chaurushiya joined from Genentech where she was a Postdoctoral Fellow in the Department of Physiological Chemistry. Prior to Genentech, she completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others.
Dr. Chaurushiya currently serves as an Observer or Member of the Boards of BlueLight Therapeutics, TMRW, Precision Nanosystems, Purigen Biosystems, Escient Pharmaceuticals, NodThera, Magnetic Insight, and Novome Biotechnologies; and was previously an Observer at Ideaya Biosciences (NASDAQ:IDYA). In addition, she is a Fellow of the Society of Kauffman Fellows and serves on the Board of Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists.
Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College.